Nanosuspensions for the Improvement of Drug Bioavailability, 2nd Edition

Dear Colleagues,

Solubility is a critical property for all drugs, which need to be dissolved in biological fluids to be absorbed and interact with their molecular target(s). The majority of new chemical entities in discovery and development, and a number of approved compounds listed in classes II and IV of the Biopharmaceutical Classification System, are characterized by poor water solubility. The same issue is shared by several natural molecules. Low solubility often results in limited or erratic bioavailability, which might impose higher doses to achieve a pharmacological effect, increasing the risk of toxicity and the waste of material. The reduction in drug particle size below 1 µm generates nanocrystals, which in the last several decades have delivered the promise of increasing drug solubility and improving bioavailability. Nanocrystals can be dispersed in aqueous or non-aqueous media to produce nanosuspensions, stabilized by surfactants or polymers if necessary. Nanosuspensions, in addition to allowing high drug concentrations, have proved to be efficient in crossing numerous biological barriers, including the skin, the pulmonary epithelium, and the intestinal wall.

This Special Issue on “Nanosuspensions for the Improvement of Drug Bioavailability” will include original research and thematic reviews on any aspects related to the development of nanosuspensions.

Specifically, the Guest Editors welcome contributions focused on production processes and characterization methods, on the development of novel nanosuspensions, and on their assay in relevant in vitro/in vivo models. Expert opinions on clinical translation and speculative hypotheses on debated topics are also invited.

Prof. Dr. Francesco Lai
Dr. Michele Schlich
Dr. Rosa Pireddu
Dr. Luca Casula
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.